As of the 3rd of February, Genmab A/S retains the Downside Deviation of 2.04, risk adjusted performance of 0.06, and Market Risk Adjusted Performance of 1.44. Genmab A/S technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Genmab A/Sstandard deviation, information ratio, treynor ratio, as well as the relationship between the variance and jensen alpha to decide if Genmab A/S is priced fairly, providing market reflects its last-minute price of 270.5 per share.
Genmab A/S's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Genmab A/S's valuation are provided below:
Gross Profit
3.6 B
Profit Margin
0.4117
Market Capitalization
17.2 B
Revenue
3.8 B
Earnings Share
4.859
There are over one hundred nineteen available fundamental trends for Genmab A/S, which can be analyzed over time and compared to other ratios. Active traders should verify all of Genmab A/S regular fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
The Net Income trend for Genmab AS offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Genmab A/S is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Genmab A/S's Net Income Growth Pattern
Below is the plot of the Net Income of Genmab AS over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Genmab A/S financial statement analysis. It represents the amount of money remaining after all of Genmab AS operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Genmab A/S's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genmab A/S's overall financial position and show how it may be relating to other accounts over time.
Understanding the fundamental principles of building solid financial models for Genmab A/S is extremely important. It helps to project a fair market value of Genmab Stock properly, considering its historical fundamentals such as Net Income. Since Genmab A/S's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Genmab A/S's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Genmab A/S's interrelated accounts and indicators.
Please note, there is a significant difference between Genmab A/S's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab A/S is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Genmab A/S's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Genmab A/S 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Genmab A/S's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Genmab A/S.
0.00
11/05/2025
No Change 0.00
0.0
In 2 months and 31 days
02/03/2026
0.00
If you would invest 0.00 in Genmab A/S on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Genmab AS or generate 0.0% return on investment in Genmab A/S over 90 days. Genmab A/S is related to or competes with BioNTech. Genmab AS, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark More
Genmab A/S Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Genmab A/S's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Genmab AS upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab A/S's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Genmab A/S's standard deviation. In reality, there are many statistical measures that can use Genmab A/S historical prices to predict the future Genmab A/S's volatility.
At this point, Genmab A/S is very steady. Genmab A/S holds Efficiency (Sharpe) Ratio of 0.0769, which attests that the entity had a 0.0769 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Genmab A/S, which you can use to evaluate the volatility of the firm. Please check out Genmab A/S's Risk Adjusted Performance of 0.06, downside deviation of 2.04, and Market Risk Adjusted Performance of 1.44 to validate if the risk estimate we provide is consistent with the expected return of 0.16%. Genmab A/S has a performance score of 6 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.0968, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Genmab A/S's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genmab A/S is expected to be smaller as well. Genmab A/S right now retains a risk of 2.12%. Please check out Genmab A/S information ratio, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to decide if Genmab A/S will be following its current trending patterns.
Auto-correlation
-0.11
Insignificant reverse predictability
Genmab AS has insignificant reverse predictability. Overlapping area represents the amount of predictability between Genmab A/S time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Genmab A/S price movement. The serial correlation of -0.11 indicates that less than 11.0% of current Genmab A/S price fluctuation can be explain by its past prices.
Correlation Coefficient
-0.11
Spearman Rank Test
-0.09
Residual Average
0.0
Price Variance
73.5
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
At this time, Genmab A/S's Operating Income is most likely to increase significantly in the upcoming years.
Based on the recorded statements, Genmab AS reported net income of 4.35 B. This is 91.56% higher than that of the Oil, Gas & Consumable Fuels sector and significantly higher than that of the Energy industry. The net income for all Germany stocks is significantly lower than that of the firm.
Did you try this?
Run Global Correlations Now
Global Correlations
Find global opportunities by holding instruments from different markets
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Genmab A/S's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Genmab A/S's managers, analysts, and investors.
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab A/S using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
When determining whether Genmab A/S offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab A/S's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Please note, there is a significant difference between Genmab A/S's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab A/S is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Genmab A/S's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.